Its numerous limitations as a drug [39] contribute to this, but the potential risk of inducing haemolytic anaemia in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PDd) enzyme activity levels is the primary limitation. The gene discussed is G6PD; the disease is non-autoimmune hemolytic anemia.